alendronate has been researched along with Prosthesis Durability in 16 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate could prevent particle-induced osteolysis." | 3.74 | [Experiment study of alendronate in the prevention and treatment of aseptic loosening of prosthesis]. ( Chen, M; Fang, ZH; Kan, WS; Zheng, Q, 2008) |
| " Because this difference has been attributed to the antiapoptotic inflammatory signals that protect osteoclasts from BP-induced apoptosis, but not RANK antagonists, we tested the hypothesis that osteoprotegerin (OPG) is more effective in preventing wear debris-induced osteolysis than zoledronic acid (ZA) or alendronate (Aln) in the murine calvaria model using in vivo micro-CT and traditional histology." | 3.74 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. ( Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R, 2008) |
| "By reducing the bone resorption after implantation of a joint replacement, it should be possible to enhance the initial fixation of the implant." | 2.74 | Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. ( Aspenberg, P; Hansson, U; Ryd, L; Toksvig-Larsen, S, 2009) |
| "Treatment with alendronate reduced the width of the fibrous loosening membrane and the number of osteoclasts at the bone-screw interface." | 1.33 | Alendronate inhibits bone resorption at the bone-screw interface. ( Azuma, Y; Miyaji, T; Nakase, T; Shimizu, N; Uchiyama, Y; Yoshikawa, H, 2005) |
| "Alendronate is a bisphosphonate that can decrease osteoclastic activity." | 1.30 | Alendronate did not inhibit instability-induced bone resorption. A study in rats. ( Aspenberg, P; Astrand, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, T | 1 |
| Chen, X | 2 |
| Zheng, M | 1 |
| Yu, H | 1 |
| Zhang, S | 1 |
| Sun, S | 1 |
| Guo, H | 1 |
| Jin, Q | 1 |
| Ji, WP | 1 |
| Wang, XL | 1 |
| Ma, MQ | 1 |
| Lan, J | 1 |
| Li, H | 1 |
| O'Neill, BJ | 1 |
| O'hEireamhoin, S | 1 |
| Morrissey, DI | 1 |
| Keogh, P | 1 |
| Chen, M | 1 |
| Zheng, Q | 1 |
| Fang, ZH | 1 |
| Kan, WS | 1 |
| Hansson, U | 1 |
| Toksvig-Larsen, S | 1 |
| Ryd, L | 1 |
| Aspenberg, P | 3 |
| Zeng, Y | 1 |
| Lai, O | 1 |
| Shen, B | 1 |
| Yang, J | 1 |
| Zhou, Z | 1 |
| Kang, P | 1 |
| Pei, F | 1 |
| Qu, S | 1 |
| Bai, Y | 1 |
| Liu, X | 1 |
| Fu, R | 1 |
| Duan, K | 1 |
| Weng, J | 1 |
| Astrand, J | 2 |
| Peter, B | 1 |
| Ramaniraka, N | 1 |
| Rakotomanana, LR | 1 |
| Zambelli, PY | 1 |
| Pioletti, DP | 1 |
| Miyaji, T | 1 |
| Nakase, T | 1 |
| Azuma, Y | 1 |
| Shimizu, N | 1 |
| Uchiyama, Y | 1 |
| Yoshikawa, H | 1 |
| Lewis, G | 1 |
| Janna, S | 1 |
| Jakobsen, T | 1 |
| Baas, J | 1 |
| Bechtold, JE | 2 |
| Elmengaard, B | 1 |
| Søballe, K | 2 |
| Jensen, TB | 1 |
| Kidder, L | 1 |
| Tsutsumi, R | 1 |
| Hock, C | 1 |
| Bechtold, CD | 1 |
| Proulx, ST | 1 |
| Bukata, SV | 1 |
| Ito, H | 1 |
| Awad, HA | 1 |
| Nakamura, T | 1 |
| O'Keefe, RJ | 1 |
| Schwarz, EM | 1 |
| Frenkel, SR | 1 |
| Jaffe, WL | 1 |
| Valle, CD | 1 |
| Jazrawi, L | 1 |
| Maurer, S | 1 |
| Baitner, A | 1 |
| Wright, K | 1 |
| Sala, D | 1 |
| Hawkins, M | 1 |
| Di Cesare, PE | 1 |
1 review available for alendronate and Prosthesis Durability
| Article | Year |
|---|---|
A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA.
Topics: Alendronate; Arthroplasty, Replacement, Hip; Bone Cements; Bone Density; Bone Density Conservation A | 2011 |
1 trial available for alendronate and Prosthesis Durability
| Article | Year |
|---|---|
Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Knee; Bone De | 2009 |
14 other studies available for alendronate and Prosthesis Durability
| Article | Year |
|---|---|
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Hum | 2018 |
Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Densit | 2013 |
Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture.
Topics: Alendronate; Bone Density Conservation Agents; Device Removal; Female; Femoral Fractures; Fracture F | 2014 |
[Experiment study of alendronate in the prevention and treatment of aseptic loosening of prosthesis].
Topics: Alendronate; Animals; Cytokines; Female; Humans; Joint Prosthesis; Joints; Male; Osteolysis; Prosthe | 2008 |
Study on in vitro release and cell response to alendronate sodium-loaded ultrahigh molecular weight polyethylene loaded with alendronate sodium wear particles to treat the particles-induced osteolysis.
Topics: Alendronate; Animals; Coculture Techniques; Macrophages; Mice; Osteoblasts; Osteolysis; Particle Siz | 2013 |
Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening.
Topics: Administration, Topical; Alendronate; Animals; Disease Models, Animal; Male; Movement; Osteolysis; P | 2004 |
Peri-implant bone remodeling after total hip replacement combined with systemic alendronate treatment: a finite element analysis.
Topics: Administration, Oral; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Remodeling; Co | 2004 |
Alendronate inhibits bone resorption at the bone-screw interface.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Bone Screws; Cathepsin K; Cathepsins; Disea | 2005 |
Alendronate in bone cement: fatigue life degraded by liquid, not by powder.
Topics: Alendronate; Arthroplasty, Replacement; Biomechanical Phenomena; Bone Cements; Materials Testing; Pa | 2006 |
Soaking morselized allograft in bisphosphonate can impair implant fixation.
Topics: Alendronate; Animals; Arthroplasty, Replacement; Biomechanical Phenomena; Bone Density Conservation | 2007 |
Alendronate treatment in the revision setting, with and without controlled implant motion: an experimental study in dogs.
Topics: Alendronate; Animals; Arthroplasty, Replacement; Bone Density Conservation Agents; Bone Resorption; | 2007 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Dis | 2008 |
Alendronate did not inhibit instability-induced bone resorption. A study in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Disease Models, Animal; Drug Evaluation, Preclin | 1999 |
The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Plates; Bone Remodeling; Disease Models, | 2001 |